Nippon Life Global Investors Americas Inc. Invests $4.67 Million in Edwards Lifesciences Corporation $EW

Nippon Life Global Investors Americas Inc. bought a new position in Edwards Lifesciences Corporation (NYSE:EW) during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 51,670 shares of the medical research company’s stock, valued at approximately $4,674,000.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in EW. Mirae Asset Global Investments Co. Ltd. increased its position in Edwards Lifesciences by 27.3% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 109,749 shares of the medical research company’s stock worth $9,356,000 after purchasing an additional 23,514 shares during the last quarter. Norges Bank purchased a new stake in Edwards Lifesciences during the fourth quarter valued at $803,686,000. TD Asset Management Inc lifted its position in Edwards Lifesciences by 6.4% during the fourth quarter. TD Asset Management Inc now owns 778,129 shares of the medical research company’s stock valued at $66,335,000 after purchasing an additional 47,051 shares during the last quarter. Intech Investment Management LLC lifted its position in Edwards Lifesciences by 22.2% during the fourth quarter. Intech Investment Management LLC now owns 69,347 shares of the medical research company’s stock valued at $5,912,000 after purchasing an additional 12,591 shares during the last quarter. Finally, Fideuram Intesa Sanpaolo Private Banking S.P.A. purchased a new position in shares of Edwards Lifesciences in the 4th quarter worth $1,626,000. 79.46% of the stock is owned by institutional investors.

Insider Buying and Selling

In related news, SVP Andrew M. Dahl sold 568 shares of the stock in a transaction dated Friday, May 29th. The shares were sold at an average price of $86.08, for a total value of $48,893.44. Following the sale, the senior vice president directly owned 15,334 shares of the company’s stock, valued at $1,319,950.72. This represents a 3.57% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, VP Daniel J. Lippis sold 619 shares of the business’s stock in a transaction that occurred on Tuesday, August 11th. The shares were sold at an average price of $92.03, for a total value of $56,966.57. Following the transaction, the vice president owned 40,034 shares of the company’s stock, valued at $3,684,329.02. This trade represents a 1.52% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 25,570 shares of company stock valued at $2,219,390 in the last ninety days. 0.31% of the stock is owned by company insiders.

Edwards Lifesciences Trading Down 0.1%

EW stock opened at $91.51 on Monday. The company has a quick ratio of 3.77, a current ratio of 4.52 and a debt-to-equity ratio of 0.06. Edwards Lifesciences Corporation has a twelve month low of $72.30 and a twelve month high of $96.29. The stock has a market capitalization of $52.69 billion, a price-to-earnings ratio of 52.59, a price-to-earnings-growth ratio of 2.30 and a beta of 0.85. The firm’s fifty day simple moving average is $88.73 and its two-hundred day simple moving average is $84.38.

Edwards Lifesciences (NYSE:EW) last announced its earnings results on Thursday, July 23rd. The medical research company reported $0.78 earnings per share for the quarter, beating the consensus estimate of $0.74 by $0.04. The business had revenue of $1.74 billion for the quarter, compared to the consensus estimate of $1.70 billion. Edwards Lifesciences had a net margin of 15.43% and a return on equity of 15.68%. The business’s revenue for the quarter was up 13.6% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.67 earnings per share. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. As a group, analysts anticipate that Edwards Lifesciences Corporation will post 3 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on EW shares. Weiss Ratings restated a “hold (c)” rating on shares of Edwards Lifesciences in a report on Friday, July 17th. Mizuho increased their price target on shares of Edwards Lifesciences from $100.00 to $105.00 and gave the company an “outperform” rating in a report on Wednesday, July 15th. BTIG Research lifted their price target on Edwards Lifesciences from $100.00 to $110.00 and gave the stock a “buy” rating in a research report on Tuesday, June 30th. Evercore reissued an “outperform” rating and set a $100.00 price objective on shares of Edwards Lifesciences in a research note on Monday, July 6th. Finally, TD Cowen restated a “buy” rating on shares of Edwards Lifesciences in a research report on Tuesday, July 21st. Seventeen research analysts have rated the stock with a Buy rating and six have given a Hold rating to the stock. Based on data from MarketBeat, Edwards Lifesciences presently has a consensus rating of “Moderate Buy” and an average price target of $100.27.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.